Post-menopausal hormone replacement therapy (cont'd): Risk-benefit balance in the hot seat

Prescrire International

Volumn 13, Issue 71, 2004, Pages 106-109

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTROGEN; GESTAGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NANDROLONE; PLACEBO; TIBOLONE; CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE;

ADULT; BREAST CANCER; CANCER GRADING; CANCER RISK; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; DEMENTIA; DISEASE SEVERITY; DRUG USE; EXPERIENCE; FEMALE; FOLLOW UP; FRANCE; HEART INFARCTION; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; INTERPERSONAL COMMUNICATION; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MONOTHERAPY; PATIENT MONITORING; POSTMENOPAUSE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SECONDARY PREVENTION; SWEDEN; THROMBOEMBOLISM; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR VOLUME; ARTICLE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; ESTROGEN THERAPY; EUROPE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TIME; UNITED STATES; WOMEN'S HEALTH;

BREAST NEOPLASMS; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; DEMENTIA; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); EUROPE; FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; THROMBOEMBOLISM; TIME FACTORS; UNITED STATES; WOMEN'S HEALTH;

EID: 3142697179     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Prescrire Editorial Staff "Postmenopausal hormone therapy: cardiovascular risks" Prescrire Int 2003; 12 (64): 65-69.
2. Prescrire Rédaction "Traitement hormonal substitutif de la ménopause et cancer: attention au sein" Rev Prescrire 2003; 23 (235): 28.
3. Cauley JA et al. "Effects of estrogen plus progestin on risk of fracture and bone mineral density. The Women's Health Initiative randomized trial" JAMA 2003; 290 (13): 1729-1738.
4. Chlebowski RT et al. "Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women's Health Initiative randomized trial" JAMA 2003; 289 (24): 3243-3253.
5. Wassertheil-Smoller S et al. "Effect of Estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial" JAMA 2003; 289 (20): 2673-2684.
6. Manson JE et al. "Estrogen plus progestin and the risk of coronary heart disease" N Engl J Med 2003; 349 (6): 523-534.
7. Shumaker SA et al. "Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial" JAMA 2003; 289 (20): 2651-2662.
8. Rapp SR et al. "Effect of estrogen plus progestin on global cognitive function in postmenopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial" JAMA 2003; 289 (20): 2663-2672.
9. Grady D et al. "Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/Progestin Replacement Study" Am J Med 2002; 113: 543-548.
10. The Esprit team "Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial" Lancet 2002; 360 (9350): 2001-2008.
11. Prescrire Rédaction "Médicaments du traitement hormonal substitutif de la ménopause: peu de critères de choix" Rev Prescrire 2003; 23 (242): 610-613.
12. Million women study collaborators "Breast cancer and hormone-replacement therapy in the Million Women Study" Lancet 2003; 362: 419-427.
13. Lagro-Janssen T et al. "Breast cancer and hormone-replacement therapy: up to general practice to pick up the pieces" Lancet 2003; 362: 414-415.
14. Olsson HL et al. "Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden" Cancer 2003; 97 (6): 1387-1392.
15. Li CI et al. "Relationship between long durations and different regimens of hormone therapy and risk of breast cancer" JAMA 2003; 289 (24): 3254-3263.
16. Scarabin PY et al. "Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk" Lancet 2003; 362: 428-432.
17. Anderson GL et al. "Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures. The Women's Health Initiative randomized trial" JAMA 2003; 290: 1739-1748.
18. Prescrire Editorial Staff "Tibolone" Prescrire Int 2002; 11 (59): 79-82.
19. "Estradiol for implants". In: "British National Formulary" British Medical Association - Royal Pharmaceutical Society of Great Britain, London. Website http://www.bnf.org consulted on 21 October 2003.
20. Prescrire Rédaction "désogestrel+éthinylestradiol-Mercilon" Rev Prescrire 1991; 11 (103): 8.
21. Prescrire Rédaction "gestodène+éthinylestradiol-Moneva, Minulet" Rev Prescrire 1991; 11 (110): 398.
22. Prescrire Editorial Staff "Third-generation oral contraceptives and increased risk of thromboembolism" Prescrire Int 1996; 5 (22): 50-52.
23. Agence française de sécurité sanitaire des produits de santé "Actualisation des recommandations sur le traitement hormonal substitutif" 3 December 2003 + "Mise au point actualisée sur le traitement hormonal substitutif de la mé nopause (THS) - décembre 2003". Website http://afssaps.sante.fr consulted on 10 December 2003.
24. The European Agency for the Evaluation of Medicinal Products "EMEA public statement on recent publications regarding hormone replacement therapy" 3 December 2003. Website http://www.emea.eu.int consulted on 10 December 2003.
25. Medicines and Healthcare Products Regulatory Agency "Further advice on safety of hormone replacement therapy (HRT)" 3 december 2003 + "Hormone replacement therapy (HRT): latest safety update (updated 3 December 2003)" 3 December 2003. Website http://www.mhra.gov.uk consulted on 10 December 2003.
26. French datasheet compendium "Farlutal". In: "Dictionnaire Vidal", Paris 1968: 535.